View More View Less
  • 1 Gyógyszerügyi Management és Szervezés, Debreceni Egyetem OEC, Debrecen, 2083, Solymár, Tölgy u. 7.
Restricted access

Absztrakt

Annak az ismert régi észleletnek a modern patobiokémiai magyarázata, miszerint a daganatos betegekben szignifikánsan magasabb a tromboembóliás komplikációk előfordulása, ma már kezd körvonalazódni, mind a daganatsejtek által termelt prokoaguláns tényezők, mind pedig az alvadási fibrinolitikus rendszer regulációjának megváltozása alapján. Továbbmenve, az ismert kemoterápiás szerek önmagukban is fokozhatják a trombózisrizikót. Ennek részleteit, az ismert gyógyszereket és patobiokémiai alapokat tekinti át a cikk, kitekintve végül új adjuváns hatásokra a direkt antikoagulánsokkal kapcsolatosan.

  • 1. H Al-Mondhiry 1983 Beta thromboglobulin and platelet factor 4 in patients with cancer Am J Hematol 14 105.

  • 2. UH Athale AKC Chan 2007 Thromboembolic complications in pediatric hematologic malignancies Semin Thromb Hemost 33 416 426.

  • 3. T Barbui G Finazzi 1999 Management of essential thrombocythemia Crit Rev Oncol Hematol 29 257 266.

  • 4. CL Bennett CC Tigue BA Angelotta 2007 Adverse effect of drugs used to treat hematologic malignancies: Surveillance Effort from the Research on Adverse Drug Events and Reports Project Semin Thromb Hemost 33 365 372.

    • Search Google Scholar
    • Export Citation
  • 5. MC Bertomeu S Gallo D Lauri 1990 Chemotherapy enhances endothelial reactivity to platelets Clin Exp Metast 8 511 518.

  • 6. JF Bohlius S Langensiepen A Engert 2005 Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review Best Pract Res Clin Haematol 18 449 454.

    • Search Google Scholar
    • Export Citation
  • 7. PF Bross J Beitz G Chen 2001 Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin Cancer Res 7 1490 1496.

    • Search Google Scholar
    • Export Citation
  • 8. L Canobbio F Boccardo D Guarneri 1991 Phase II study of navelbine in advanced renal cell carcinoma Eur J Cancer Clin Oncol 27 804 805.

    • Search Google Scholar
    • Export Citation
  • 9. VA Carrol BR Binder 1999 The role of the plasminogen activation system in cancer Semin Thromb Hemost 25 183 197.

  • 10. NH Dang FB Hagemeister B Pro 2004 Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 22 4095 4102.

    • Search Google Scholar
    • Export Citation
  • 11. A Falanga M Marchetti T Barbui 2002 All-trans-retinoic acid and bleeding/thrombosis Pathophysiol Haemost Thromb 1 Suppl 19 21.

  • 12. A Falanga M Marchetti 2007 Heparin in tumor progression and metastatic dissemination Semin Thromb Hemost 33 688 694.

  • 13. A Falanga FR Rickles 1999 Pathophysiology of the thrombophilic state in the cancer patient Semin Thromb Hemost 25 173 182.

  • 14. P Fernandez SR Patierno FR Rickles 2004 Tissue factor and fibrin in tumor angiogenesis Semin Thromb Hemost 30 31 44.

  • 15. BD Humphreys JP Sharman JM Henderson 2004 Gemcitabine-associated thrombotic microangiopathy Cancer 100 2664 2670.

  • 16. AK Kakkar AR Hedges CR Williamson 1995 Perioperative heparin therapy increases late deaths from metastatic cancer Int J Oncol 6 885 888.

    • Search Google Scholar
    • Export Citation
  • 17. AA Khorana RL Fine 2004 Pancreatic cancer and thromboembolic disease Lancet Oncol 5 655 663.

  • 18. MD Kohli V Kaushal P Mehta 2003 Role of coagulation and fibrinolytic system in prostate cancer Semin Thromb Hemost 29 301 308.

  • 19. O Kucuk HC Kwaan W Gunnar RM Vazquez 1985 Thromboembolic complication associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma Cancer 55 702 706.

    • Search Google Scholar
    • Export Citation
  • 20. HC Kwaan S Palmar J Wang 2003 Pathogenesis of increased risk of thrombosis in cancer Semin Thromb Hemost 29 283 290.

  • 21. AYY Lee 1999 The thrombophilic state induced by therapeutic agents in the cancer patient Semin Thromb Hemost 25 137 146.

  • 22. S Lentzsch R LeBlanc K Podar 2003 Immunomodulatory analogues of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Lancet 17 41 44.

    • Search Google Scholar
    • Export Citation
  • 23. J Litz G Sakuntala Warshamana-Greene G Sulanke 2004 The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression Lung Cancer 46 283 291.

    • Search Google Scholar
    • Export Citation
  • 24. Magyar Thrombosis és Haemostasis Társaság Konszenzus Nyilatkozata a Thromboemboliás megbetegedések prevenciója és kezelése tárgyában. Szerk: Pfliegler Gy és mtsai, Hematológiai Transzfuziológia S2:3-46, 2005.

    • Search Google Scholar
    • Export Citation
  • 25. PA Martorana H Göbel M Just RE Nitz 1986 Effect of molsidomine on platelet-mediated thrombosis in stenosed canine coronary arteries J Mol Cell Cardiol 18 Suppl 1 100.

    • Search Google Scholar
    • Export Citation
  • 26. K Miralem 1996 Antiangiogenic properties of heparins J Biol Chem 271 17100 17106.

  • 27. J Pander H Gelderblom HJ Guchelaar 2007 Pharmacogenetics of EGFR and VEGF inhibition Drug Discovery Today 12 1054 1060.

  • 28. R Pérez-Soler A Chachoua LA Hammond 2004 Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 3238 3247.

    • Search Google Scholar
    • Export Citation
  • 29. JP Pujol JL Breton R Gervais 2007 Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC J Clin Oncol 25 3945 3951.

    • Search Google Scholar
    • Export Citation
  • 30. P Rajvanshi HM Shulman EL Sievers GB McDonald 2002 Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy Blood 99 23010 23014.

    • Search Google Scholar
    • Export Citation
  • 31. C Rella M Coviello M Quaranta A Paradiso 1993 Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer Thromb Res 69 209 220.

    • Search Google Scholar
    • Export Citation
  • 32. T Shapner DC Tormey R Gray 1991 Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer J Clin Oncol 9 286 294.

    • Search Google Scholar
    • Export Citation
  • 33. MR Sherman FB Tuazon LK Miller 1980 Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol Endocrinol 106 1715 1727.

    • Search Google Scholar
    • Export Citation
  • 34. S Simonneau S Lapota P Mismetti 2006 A randomised study comparing the efficacy and safety of nadroparine 2850 UI vs. enoxaparine 4000 UI in the prevention of venous thromboembolism after colorectal surgery for cancer J Thromb Hemost 4 1693 1700.

    • Search Google Scholar
    • Export Citation
  • 35. S Singhal J Mehta 2002 Thalidomide in cancer Biomed Pharmacother 56 4 12.

  • 36. NE Tsopanoglu ME Maragoudakis 2004 Role of thrombin in angiogenesis and tumor progression Semin Thromb Hemost 30 63 70.

  • 37. LD Wagman MF Baird CL Bennett 2006 Venous thromboembolic disease. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4 838 869.

    • Search Google Scholar
    • Export Citation
  • 38. MZ Wojtukiewicz E Sierko Z Sawicki 2007 Expression of tissue factor (TF), tissue factor pathway inhibitor (TFPI), factor IX and factor X in breast cancer: comparison between primary tumor and metastatic lesions in regional lymph nodes Thromb Res 120 Suppl 2 S154.

    • Search Google Scholar
    • Export Citation
  • 39. A Zakarija HC Kwaan 2007 Adverse effects of hemostatic function of drugs used in hematologic malignancies Semin Thromb Hemost 33 355 364.

    • Search Google Scholar
    • Export Citation